Pharmaceutical News

May 15, 2020

Rubraca Receives New Indication

May 15, 2020 – The U.S. FDA has approved a new indication for Rubraca® (rucaparib), manufactured by Clovis Oncology. Rubraca is now indicated to treat adult patients who have
May 8, 2020

May 8, 2020 – The U.S. FDA has approved RetevmoTM (selpercatinib), manufactured by Eli Lilly, to treat certain patients who have lung or thyroid cancer and RET gene alterations.